Soleno Therapeutics (SLNO) Change in Accured Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 692.38% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 919.47% increase from a year earlier, with the FY2025 full-year figure at $14.1 million, up 4005.8% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $11.7 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for SLNO reached as high as $11.7 million in Q4 2025 and fell as low as -$4.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $706588.2 across 5 years, with a median of $37000.0 in 2022.
• Across the five-year window, Change in Accured Expenses plunged 1017.79% in 2024 and soared 4311.91% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.5 million in 2022, then slumped by 36.66% to $976000.0 in 2023, then plunged by 128.38% to -$277000.0 in 2024, then surged by 4311.91% to $11.7 million in 2025, then plunged by 133.89% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.0 million in Q1 2026, $11.7 million in Q4 2025, and -$962000.0 in Q3 2025.